OMEICOS’ OMT-28 Headed for Phase 3 in Primary Mitochondrial Diseases (PMD) Following Positive End-of-Phase 2 Meeting with the FDA
· omeicos therapeutics gmbh
Source Summary
OMEICOS has successfully completed the End-of-Phase 2 (EOP2) meeting with the U.S. FDA enabling a pivotal study in Primary Mitochondrial Disease (PMD).
Advertisement